Subscribe

0

  • Sign in with Email

By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.

Don’t have an account? Signup

  • Bookmarks
  • My Profile
  • Log Out
  • NEWS
  • POLICIES
  • MSME OPPORTUNITIES
  • BANKING & FINANCE
  • TECHNOLOGY FOR SMES
  • SECTORS
  • GLOBAL
  • Investment
  • LEGAL
  • KNOWLEDGE QUEST
  • Future Ready Forum 2025
  • Ek Nayi Udaan
  • Future Ready Summit 2024
  • SMB RISE
  • ADVERTISE WITH US
ad_close_btn
  • News
  • Policies
  • Banking & Finance
  • MSME Opportunities
  • Web Stories
  • InFocus
  • Technology For SMEs
  • Sectors
  • Global
  • Fashion

Powered by :

You have successfully subscribed the newsletter.
Finance InFocus

Hester Biosciences Q1FY24 Net Profit Up 88% to Rs. 6.71 Crore

Company reported revenue from operations of Rs. 87.85 crore for the Q1FY24, growth of 73% Y-o-Y as compared to revenue of Rs. 50.70 crore in Q1FY23.

author-image
SMEStreet Edit Desk
09 Aug 2023 00:00 IST
Updated On 09 Aug 2023 06:09 IST

Follow Us

New Update
Hester Biosciences Limited, SMEStreet

Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 6.71 crore in Q1FY24 ended June 2023 as against net profit of Rs. 3.56 crore in Q1FY23, growth of 88%. Company reported revenue from operations of Rs. 87.85 crore for the Q1FY24, growth of 73% Y-o-Y as compared to revenue of Rs. 50.70 crore in Q1FY23. Operating profit during Q1FY24 ended June 2023 was reported at Rs. 14.36 crore, 93% growth Y-o-Y from Rs. 7.43 crore in Q1FY23. EPS for Q1FY24 was reported at Rs. 7.89 per share.

Consolidated results include operations of subsidiaries from Nepal and Tanzania. Hester Nepal had a turnover of Rs. 6.54 Crore primarily from exports of vaccines with overall Net Profit of Rs. 3.67 Crore during Q1 FY24. Hester Africa has registered export sales of Rs.  1.76 Crore.

Consolidated Financial Highlights (Rs. cr)

Divisions

Q1

FY23

FY24

FY23

Change %

Revenue from operations

87.85

50.70

73%

266.09

EBITDA

14.36

7.43

93%

50.61

PAT (excl. OCI)

6.71

3.56

88%

28.04

EPS (In Rs., not annualized)

7.89

4.19

88%

32.96

Animal Healthcare Division

The Animal Healthcare division grew by 93%. The increase in domestic sales of this division is attributed to:

  1. A boost in demand for Goat Pox Vaccine (GPV) consequent to the Government advisory to carry out the annual preventive vaccination program for Lumpy Skin Disease (LSD) in cattle as well as towards the sale of PPR vaccine towards the National PPR Immunization program of GoI.
  2. The continued growth in sales of health products resulting from the earlier investments in expansion of sales force, territorial expansion and new product introductions.

Poultry Healthcare Division

The Poultry Healthcare division experienced de-growth of 13% in sales of Q1. Domestic sales continued to be hit due to by the recession in the poultry industry, though it is now showing an upward trend.

Petcare Division

Petcare division which was launched last year, has registered promising sales of Rs. 0.80 Crore in Q1 FY24. Petcare products have been well received in the market as reflected by a steady upward trend in month-on-month sales.

Top News Q1FY23 Poultry Healthcare Hester Biosciences Limited Animal Healthcare Net Profit Corporate Revenue SMEStreet
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news
logo

Related Articles
Read the Next Article
Latest Stories
Subscribe to our Newsletter! Be the first to get exclusive offers and the latest news

Latest Stories
Latest Stories
    Powered by


    Subscribe to our Newsletter!




    Powered by
    Select Language
    English

    Share this article

    If you liked this article share it with your friends.
    they will thank you later

    Facebook
    Twitter
    Whatsapp

    Copied!